Hinge Health CFO James Budge Sells $4.9M in Shares Through 10b5-1 Plan

Hinge Health CFO James Budge sold $4.9 million of company stock on October 12, 2026. He executed the transaction under a pre-arranged trading plan while the firm's equity trades near 52-week highs. The sale follows a 178% increase in the Hinge Health (HNGE) share price over the last six months.

"The sales were conducted under a Rule 10b5-1 trading plan adopted on June 11, 2026," according to recent SEC filings regarding the transaction.

Transaction Details and Remaining Holdings

Budge offloaded 47,720 shares of Class A common stock at an aggregate value of $4,921,577. He disclosed the sale in Form 144 filings submitted to the SEC on October 14, 2026. Following this transaction, Budge retains direct ownership of 296,728 shares of Hinge Health Class A common stock.

As of October 19, 2026, Hinge Health shares were trading at $103.96. The timing of the sale coincides with a period of growth for the digital musculoskeletal health company, which has seen its stock price climb since the spring of 2026.

Understanding Rule 10b5-1 Plans

Corporate insiders, such as chief financial officers, utilize Rule 10b5-1 trading plans to sell company stock while avoiding concerns regarding insider trading. Under these plans, an executive establishes a pre-determined schedule for selling shares at specific times or prices. This removes the discretion to trade based on non-public information.

Because the sale parameters are set in advance, specifically on June 11, 2026, the executive is protected from allegations that they timed the sale to capitalize on market fluctuations or internal developments. This mechanism is standard practice for senior leadership teams managing equity positions in public companies, providing a transparent and compliant pathway for liquidity.